Sweet, tart, and vibrantly red, raspberries are more than just a delicious fruit—they're a nutritional powerhouse. Their soft, slightly fuzzy texture and naturally refreshing taste make them a great addition to smoothies, yoghurt bowls, oatmeal, and salads. But what makes raspberries truly stand out is their impressive health profile. Rich in fiber, antioxidants, and vitamin C, these berries offer multiple benefits for your heart, digestion, blood sugar, and immune system.

Gut Health and Regular Digestion

One standout feature of raspberries is their fibre content. Just one cup delivers 8 grams of fibre, nearly a third of the recommended daily intake for women. “This high fiber content promotes healthy digestion and regular bowel movements,” says Elizabeth Harris, a registered dietitian. Raspberries are especially rich in insoluble fiber, which adds bulk to stool and helps it move more easily through the digestive tract. This can reduce the risk of constipation and support overall gut health.

A Heart-Healthy Snack

Raspberries also support cardiovascular health. While their vitamin C and fibre content are well-known, they also offer potassium, a mineral that plays a key role in managing blood pressure. Research has shown that regular consumption of raspberries may improve cholesterol levels, especially in individuals with high cholesterol or metabolic syndrome. These effects are likely linked to the berry’s mix of fiber and polyphenols, plant compounds known for their antioxidant properties.

Balanced Blood Sugar Levels

For people with diabetes or prediabetes, raspberries are an ideal fruit. They’re low in sugar and high in fibre, which helps prevent spikes in blood glucose levels. According to the American Diabetes Association, berries are one of the healthiest carbohydrate sources. When paired with protein or healthy fats like Greek yogurt or nuts, raspberries become a satisfying, blood sugar-friendly snack.

Fighting Inflammation With Antioxidants

Raspberries contain powerful antioxidants, including anthocyanins and polyphenols, which help combat inflammation and oxidative stress in the body. “These compounds can lower the risk of chronic conditions like heart disease and cancer,” Harris explains. Their anti-inflammatory properties also make raspberries a key component of the MIND diet, which supports brain health and may slow cognitive decline.

Immunity Boost With Vitamin C

With over a third of your daily vitamin C needs in just one cup, raspberries can help keep your immune system strong. Vitamin C supports wound healing, protects cells from free radical damage, and strengthens your body’s defence against infections.

Tips for Storage And Enjoyment

To keep raspberries fresh, store them in an airtight container lined with paper towels and refrigerate. Wait to rinse until you’re ready to eat. For longer storage, freeze them in a single layer before transferring to a sealed bag.

Whether eaten plain, swirled into chia seed jam, blended into smoothies, or sprinkled on cereal, raspberries are a versatile and nutrient-rich fruit worth making a regular part of your diet.

Wildfires are a big concern for US citizens. Since the beginning of 2025, 31,039 wildfires have consumed 1.3 million acres of US land, according to the National Interagency Fire Center. Wildfires are uncontrolled fires that burn wildland and often rural areas. These fires can exhaust forests, grasslands, and many other ecosystems. With the amount of smoke generated, wildfires can severely affect the health of people.

A new study suggests that wildfires might indirectly raise the risk of flu and COVID-19 outbreaks. The smoke from wildfires often forces people to stay indoors, and when more people are gathered in enclosed spaces, infectious diseases can spread more easily. This finding was recently published in the journal PLOS Climate.

Why Staying Inside Puts You at Higher Risk

When wildfires burn, the air outside gets filled with smoke, making people go indoors. This creates perfect conditions for illnesses like the flu to spread, as a researcher from Georgetown University explained. With more people packed together, germs can jump from one person to another more easily. But there's a simple way to lower this risk: just wearing a mask indoors can help a lot.

Following People's Movements During Wildfires

Researchers looked at mobile phone data to see where people went during wildfires. This data showed visits to over 4.6 million places across the U.S., both inside and outside. They focused on the wildfire season in Oregon and Washington in 2020. By checking air quality, they found the areas worst affected by smoke. During that time, especially in August and September 2020, widespread wildfires caused a lot of smoke in these states.

More People, More Risk

The study found a clear increase in indoor activities when the wildfires were burning. In counties across Oregon, indoor activity went up by 14%, and in Washington counties, it increased by almost 11%. Major cities also saw a significant jump: Seattle experienced a 16% rise, and Portland saw an 11% increase in people spending time indoors. This shift means more people were confined together.

Using computer models, the researchers confirmed that more people indoors raises the risk of infectious diseases spreading, especially for highly contagious illnesses like flu and COVID-19. But these models also showed that wearing masks indoors can help slow the spread. They found that even a small increase in mask wearing (just 10% more people) could lower the number of new cases during wildfires. In areas hit hardest by smoke, like parts of Oregon and Washington, more than half the people might need to wear masks to effectively control the disease.

Preparing for Health Risks in a Changing Climate

The researchers advise public health experts to be aware of this connection if wildfire smoke reaches their communities. They should also warn people about the higher risk of infection. The study emphasized that as we face more extreme weather events, our public health plans need to change. We have to address not just the direct environmental harm from wildfires, but also how people react and adapt to these emergencies. By understanding how people behave and planning for it, we can better protect everyone's health in a world where extreme events are becoming more common.

Being one of the most common cancer diagnoses, skin cancer claims more than two people every hour. The Skin Cancer Foundation also specifies that having five or more sunburns doubles your risk of melanoma, which is a type of skin cancer. Despite the fact that people are often urged to wear sunscreen and take protection from heat, one in five Americans will develop skin cancer by the age of 70. However, the survival rate of melanoma is 99 percent, meaning if people can get it diagnosed early, they can get proper treatment. So, how can one get an early diagnosis?

An experimental AI tool called PanDerm shows promising results in accelerating the detection of melanoma and other skin conditions, according to a new study published in Nature Medicine. When doctors used PanDerm, it improved the accuracy of skin cancer diagnoses by 11%, and the accurate diagnosis of other skin conditions by almost 17%.

Enhancing Clinical Decision-Making

PanDerm is made in a way to assist doctors by helping them understand complex imaging data and make more confident and informed decisions. While a lot of people are skeptical of the use of AI and how it may impact human lives in the long rn, the study shows that using it to work alongside professionals can help us reach great medical heights.

Researchers explained the tool is built to work alongside medical professionals, making it easier for them to interpret difficult images and choose the right course of action with greater certainty. This support is especially important because about 70% of people experience some kind of skin condition, making it crucial to spot them early for better treatment outcomes.

How PanDerm Works

Developed by a global research team, PanDerm was trained on a massive collection of over 2 million skin images, using four different types of medical imaging. Unlike previous AI models that struggled to combine various data types, PanDerm was specifically created to identify a wide range of skin conditions. It uses images from tiny microscopic slides to wide views showing lesions and the surrounding skin.

Researchers also said that by training PanDerm with diverse data from different imaging techniques, they've created a system that can understand skin conditions similar to how dermatologists do—by combining information from various visual sources.

Impressive Performance and Future Potential

In the study, PanDerm was tested on various tasks related to skin health, including screening for cancer, counting moles, tracking changes in lesions, and diagnosing a broad spectrum of skin conditions. The AI consistently delivered strong results, often needing only 5% to 10% of the data that doctors typically require for diagnoses. This means it can provide accurate results with much less information.

This AI tool could be especially valuable in areas where it's hard to see a dermatologist, as researcher Peter Soyer pointed out. However, the researchers stress that PanDerm needs more evaluation and real-world testing in different healthcare settings and with various types of patients before it can be approved and widely used.

Treatment For Skin Cancer

The Cancer Research UK explains that when you have skin cancer, the main treatment is usually surgery. However, depending on where the cancer is, how big it is, and your overall health, you might have a different kind of treatment. Your doctor will discuss all the possible options with you.

Besides surgery, other treatments include radiotherapy, which uses high-energy rays similar to X-rays to kill cancer cells, often for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). You might also get a chemotherapy cream that uses strong drugs to destroy cancer cells, or Imiquimod cream (Aldara), which helps your body's own defenses fight the cancer.

For some types of skin cancer, doctors might suggest targeted drugs or immunotherapy. These treatments either attack specific parts of cancer cells or boost your immune system to help it kill the cancer. Another option is photodynamic therapy (PDT), which uses a special drug and light to destroy the cancer cells.

After you finish your skin cancer treatment, you'll need to have follow-up appointments to make sure everything is okay.

The U.S. Food and Drug Administration (FDA) approved Yeztugo, a powerful, long-acting injection developed by Gilead Sciences, as a twice-yearly preventive treatment against HIV. The move has ignited widespread hope among global health advocates, signaling what many believe to be the dawn of a new era in HIV prevention.

With a 99.9% success rate in preventing HIV transmission in clinical trials, this injectable therapy formally known as lenacapavir, offers a revolutionary alternative to daily pills and could dramatically reshape the global HIV landscape.

Why Is HIV Drug Approval Such a Big Deal?

For more than 40 years, HIV has eluded a vaccine. While treatment has transformed HIV into a manageable chronic condition for millions, preventing new infections has remained a formidable challenge. Daily oral PrEP (pre-exposure prophylaxis), such as Truvada, has helped, but adherence is difficult for many especially in vulnerable populations.

That’s where Yeztugo changes the game. Its unique mechanism, longevity, and ease of use have the potential to overcome the barriers of daily pill regimens. Administered once every six months by a healthcare provider, it’s the longest-lasting PrEP option ever approved.

“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, CEO of Gilead Sciences. “We believe this marks a turning point.”

How Does Yeztugo Work?

Lenacapavir is not a vaccine. Instead, it is an antiretroviral that blocks HIV from infecting immune cells and replicating. What sets it apart is its ability to stay in the body for extended periods, providing protection for six months with a single shot.

Gilead conducted two major trials to test the drug’s efficacy in over 2,000 cisgender women in sub-Saharan Africa, the injection showed 100% prevention of HIV infection.

A parallel trial involving men who have sex with men and gender-diverse individuals showed a 99.9% effectiveness rate, with only two breakthrough infections. These outcomes, published in The New England Journal of Medicine, led Science to name lenacapavir its 2024 “Breakthrough of the Year.”

Reported side effects were minimal, limited mostly to injection site irritation, headaches, and nausea.

How The New Drug Affects HIV Treatment And Prevention?

Interestingly, lenacapavir didn’t start as a preventive drug. It was initially approved in 2022 (under the brand name Sunlenca) for treating drug-resistant HIV.

Researchers at Gilead quickly recognized two features that made it ideal for prevention: its long half-life and its ability to disrupt multiple stages of the HIV life cycle.

“We saw a fantastic protective effect after just one injection—even in non-human primate studies,” said Tomas Cihlar, Gilead’s VP of Virology. “That’s when we realized we had to pursue prevention aggressively.”

Could This Replace HIV Vaccine?

In many ways, yes—at least for now. While lenacapavir isn’t a vaccine in the traditional sense, its efficacy closely mimics one. And since traditional HIV vaccine development has repeatedly hit roadblocks, some experts believe lenacapavir may be the next best thing.

“Lenacapavir used by itself for prevention is a huge breakthrough,” said Dr. David Ho of Columbia University, a pioneer in HIV research. “Its potential to curb the epidemic is enormous.”

Yet ironically, the drug’s success could make it harder to develop a conventional vaccine. Why? Because it would now be unethical to assign people a placebo in vaccine trials when such a highly effective alternative exists.

Is There A the Catch?

While the science is exciting, several real-world challenges could stand in the way of Yeztugo’s success, cost, access, and policy chief among them.

Previous injectable PrEP options like cabotegravir, approved in 2021, came with hefty price tags and have yet to make a meaningful global impact. Gilead has not yet announced pricing for Yeztugo, but there’s concern it may follow suit.

Additionally, logistical barriers remain. Yeztugo must be administered in a clinic by a healthcare provider and requires that recipients test negative for HIV before each shot. That’s a significant hurdle for high-risk individuals in low-resource settings.

“There’s huge promise here, but we’ve built a jet without a runway,” said Hui Yang of the Global Fund to Fight HIV, TB, and Malaria. “If we don’t address distribution, affordability, and systemic barriers, the science won’t matter.”

Who Gets Access To HIV Injection?

Gilead has signed royalty-free licensing deals with six manufacturers to produce lenacapavir generics in 120 low- and middle-income countries. But critics point out that many middle-income nations, such as some in Latin America, are left out.

Meanwhile, in the U.S., states with strong support for PrEP programs have already seen a 38% decline in HIV infections. In contrast, states without similar support saw a 27% increase, according to The Lancet HIV.

With Medicaid cuts looming and the Supreme Court considering a case that could overturn the requirement for insurers to cover PrEP without copays, the long-term reach of Yeztugo may be compromised.

“We could be standing on the verge of eliminating new HIV infections,” said Carl Schmid of the HIV+Hepatitis Policy Institute. “But without the right policies, this will remain a medical miracle out of reach for too many.”

What Comes Next In the HIV Battle?

Gilead is already working on a once-a-year formulation of lenacapavir to make prevention even more accessible. The Global Fund aims to reach two million new PrEP users in the next three years, and Yeztugo could be pivotal to that goal.

There’s also ongoing research into self-administered versions of the injection, which would help reduce the need for in-clinic visits—especially vital for reaching marginalized populations.

The FDA’s approval of Yeztugo is more than a regulatory milestone—it’s a paradigm shift in HIV prevention strategy. Whether this breakthrough can live up to its promise will depend on how quickly and equitably it can be delivered.